<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561350</url>
  </required_header>
  <id_info>
    <org_study_id>MISC-MSI</org_study_id>
    <nct_id>NCT03561350</nct_id>
  </id_info>
  <brief_title>Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing</brief_title>
  <official_title>Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Minimally Invasive Surgery Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Minimally Invasive Surgery Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The method to analyze the microsatellite instability (MSI) status by next-generation&#xD;
      sequencing (NGS) has been established to assess the deficiency of DNA mismatch repair (MMR)&#xD;
      system. The aim of our study is to evaluate the feasibility and reliability of this NGS&#xD;
      method by testing the circulating tumor DNA (ctDNA) in blood sample of advanced colorectal&#xD;
      cancer patients. If the result is positive, the MSI status could be easily learned without&#xD;
      the acquisition of tissue samples.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MSI status in blood sample</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>ctDNA and leucocyte are extracted from blood sample for MSI detection by ColonCore NGS panel (Burning Rock, Guangzhou, China). There are three types of MSI status, MSI-H, MSI-L and MSS.</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample of advanced colorectal cancer patients&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients hospitalized in Shanghai Minimally Invasive Surgery Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  a biopsy proven histological diagnosis of colorectal carcinoma&#xD;
&#xD;
          -  MSI status of tissue sample known by IHC or PCR method&#xD;
&#xD;
          -  willing to participate and informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of other malignant tumors&#xD;
&#xD;
          -  patients with inflammatory bowel disease&#xD;
&#xD;
          -  patients with familial adenomatous polyposis&#xD;
&#xD;
          -  patients treated by surgery or adjuvant treatment&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhenghao CAI</last_name>
    <phone>86-21-64458887</phone>
    <email>czh12005@rjh.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Minimally Invasive Surgery Canter, Ruijin hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenghai CAI, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>June 16, 2018</last_update_submitted>
  <last_update_submitted_qc>June 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microsatellite Instability</keyword>
  <keyword>Circulating Tumor DNA</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

